The report on Anti-Obesity Prescription Drugs Market by drug class (orlistat, phentermine and topiramate, bupropion and naltrexone, lorcaserin, liraglutide), distribution channel (retail pharmacy, hospital pharmacy and online pharmacy), age group (pediatric and adult) trends analysis and forecasts up to 2024 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Anti-Obesity Prescription Drugs Market is projected to grow at a CAGR of 4.97% in terms of value over the period of 2018-2024. The growth in the world market is primarily driven by significant contribution by North America (Leading region) region to this market.
For more information kindly visit : https://www.bharatbook.com/drugs-market-research-reports-396211/anti-obesity-drugs-china1.html Bharat Book Bureau provides the report, on “ Anti-Obesity Drugs Markets in China ”. China's demand for Anti-Obesity Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow.
Only one older generation drug with modest efficacy had been available until the recent arrival of two new therapies that could potentially change the prescribing landscape. Will these drugs make a significant impact on the Obesity market? Which drugs are used off-label for the treatment of obesity?
Infinium Global Research has added a new report on Global Anti-Obesity Prescription Drugs Market. The report predicts the market size of Anti-Obesity Prescription Drugs is expected to reach XX billion by 2024.
Obesity Treatment Market, By Procedure Type (Gastric Bypass, Gastric Banding, Non-Invasive Surgery, Sleeve Gastrectomy); By Products Type (Gastric Bands, Gastric Balloons, Stapling Devices, Gastric Electrical Stimulators); By Drug Type (Malabsorption & Satiety Drugs, Combination Drugs, Appetite Suppressants)]; and Geography - Trend, Analysis and Forecast
The market for injectable drug delivery is estimated to increase rapidly over the forecast period. Sedentary lifestyles have spread over the world as a result of rapid technological adoption. Obesity rates are rising as a result of this shift in lifestyle, which is leading to a slew of chronic ailments including diabetes and cardiovascular disease.
According to the latest research report by IMARC Group, The global peptic ulcer drugs market size reached US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 2.65% during 2024-2032. More Info:- https://www.imarcgroup.com/peptic-ulcer-drugs-market
World Health Organization (WHO) suggests that over 50% of the worldwide population is obese. Furthermore, in the year 2014, over 1.9 billion adults that were 18 years and above were overweight. Out of these, more than 600 million were reported obese
The growing demand for RWE solutions to get precise and clear information about the safety and efficacy of new products represents one of the key factors driving the market Get a PDF Sample for more detailed market insights: Visit the following link: https://www.imarcgroup.com/real-world-evidence-solutions-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099
Presently, the increasing global geriatric population, which is highly susceptible to diabetes and chronic cardiovascular diseases, represents one of the major factors positively influencing the market Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: Visit the following link: https://www.imarcgroup.com/congestive-heart-failure-drugs-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099
The gastrointestinal drugs market size is expected to reach $65 billion by 2022, significantly growing at a CAGR of around 4.5% during the forecast period. The growth in the gastrointestinal drugs market can be attributed to the expected increase in prevalence of obesity and digestive diseases globally. Read more at https://bit.ly/2StzjHk
The growing demand for RWE solutions to get precise and clear information about the safety and efficacy of new products represents one of the key factors driving the market Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: Visit the following link: https://www.imarcgroup.com/real-world-evidence-solutions-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099
The global diabetes drugs market was valued at $34295 million in 2018 & is estimated to generate net revenue of approximately $60434.87 million by 2027, growing at a CAGR of 6.50%.
Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared.
According to the latest research report by IMARC Group, The India over the counter (OTC) drugs market size reached US$ 7.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 19.4 Billion by 2028, exhibiting a growth rate (CAGR) of 16.7% during 2023-2028. More Info:- https://www.imarcgroup.com/india-over-the-counter-drugs-market
Obesity Management Market: Phentermine and Topiramate Expected to be the Second Most Lucrative Segment by Drug Type: Global Industry Analysis and Opportunity Assessment 2017-2027
Bharat Book Bureau provides the report on “Global Human Microbiome-based Drugs Market”, (https://www.bharatbook.com/diagnostics-market-research-reports-644540/human-microbiome-based-drugs-diagnostics-global.html) The report provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
According to the latest report by Renub Research, titled "Diabetes Drug Market Global & Forecast By Disease, Oral Therapy, Injection, Insulin, Regions, Company" Diabetes drugs are used to treat pre-diabetes and diabetes mellitus type 2 by controlling the blood glucose level of the body. There are different classes of medicine for the treatment of this diabetes, which are given to patients through oral, intravenous, and subcutaneous routes. According to Renub Research analysis, Global Diabetes Drug Market is forecasted to be US$ 78.10 Billion by 2026. This growth is due to the rising number of diabetes patients worldwide, increasing per capita income. Another reason is with the use of machines; people are following a sedentary lifestyle, which leads to obesity, a decline of physical activity, and consumption of unhealthy meals. Besides, growth in the ageing population is also one of the other reason.
Uterine polyps is also known as endometrial polyps which is characterized by the abnormal growth of the tissues from the inner lining of the endometrium (uterus) which further leads to the formation of small bean like structure known as polyps. These polyps are generally benign (non-cancerous) but eventually can change into cancerous and turn into malignant from of cancer (precancerous polyps).
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market.
According to a new market report published by Persistence Market Research “Global Market Study on Osteoporosis Drugs: AsiaPacific to Witness Highest Growth by 2022”, the global osteoporosis drugs market is estimated to be valued at US$11,226.1 Mn by the end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to 2022, to account for US$14,786.7 Mn by 2022.
According to a new market report published by Persistence Market Research “Global Market Study on Osteoporosis Drugs: AsiaPacific to Witness Highest Growth by 2022”, the global osteoporosis drugs market is estimated to be valued at US$11,226.1 Mn by the end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to 2022, to account for US$14,786.7 Mn by 2022.
Get a sample brochure @ http://tinyurl.com/j2v74bh Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
Liver disease comprises of wide range of complex conditions affecting the liver. Liver disease treatment market is assured to grow on account of unmet clinical needs and upcoming treatment modifications.
The term glycobiology, also called as glycans, is the study of structure, function and biology of carbohydrate. They are the most essential components in living things.
According to a new market report published by Persistence Market Research “Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022”, the global osteoporosis drugs market is estimated to be valued at US$11,226.1 Mn by the end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to 2022, to account for US$14,786.7 Mn by 2022.
According to a new market report published by Persistence Market Research “Global Market Study on Osteoporosis Drugs: AsiaPacific to Witness Highest Growth by 2022”, the global osteoporosis drugs market is estimated to be valued at US$11,226.1 Mn by the end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to 2022, to account for US$14,786.7 Mn by 2022.
The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsight’s report also highlights the patent, patent exclusivity information and competitive landscape.
Global Market Estimates is a market research and business consulting company who has proven track record in serving Fortune 500 companies. Request for a sample copy of the ‘Oral Anti Diabetic Drug Market’ report @: https://www.globalmarketestimates.com/oral-antidiabetic-drug-market/
The report on Metabolic Disorders Therapeutics Market by disease type (diabetes, obesity, hypercholesterolemia and lysosomal storage disease), product (metachromatic leukodystrophy, globoid leukodystrophy, hepatic encephalopathy and others) trends analysis and forecasts up to 2023 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Metabolic Disorders Therapeutics Market is projected to grow at a CAGR of 5.7% in terms of value over the period of 2017-2023. The growth in the world market is primarily driven by significant contribution by North America (Leading region) region to this market.
The world over, the high obesity rate has become a burden, and the dire need to bring it under control has risen as a result. World Health Organization (WHO) suggests that over 50% of the worldwide population is obese. Furthermore, in the year 2014, over 1.9 billion adults that were 18 years and above were overweight.
Obesity management is an evolving area of focus, which has been witnessing an upsurge in demand, due to the increasing medical tourism in countries such as Thailand, India, Singapore, and Malaysia. Medical tourism is a growing sector for many middle-income countries as packages for countries such as India and Thailand cost low and constitute insurance coverage.
Big Market Research, PharmaPoint: Global Asthma Drug Market Size, Share, Strategies, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities. Big Market Research added a new research report "PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023". Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade. The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children. Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Global oncology drugs market is projected to grow at a brisk rate over the forecast period owing to widespread prevalence of cancer, globally. Various other related factors which are contributing to the growth of oncology drugs market include rise in geriatric population worldwide, increase in global healthcare expenditure, rising number of product approvals by regulatory bodies and growing R&D activities for the development of new cancer drugs.
According to a new market report published by Persistence Market Research “Global Market Study on Diabetic Nephropathy Market – Asia to Witness Highest Growth by 2020,”.The global diabetic nephropathy market was valued at USD 2,262.2 million in 2014 and is expected to grow at a CAGR of 5.6% from 2014 to 2020, to reach an expected value of USD 3,145.9 million in 2020. Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Globally, the diabetic nephropathy market is witnessing significant growth due to increasing prevalence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development and raising awareness about diabetes and kidney-related disorders are also driving the growth of the market.
Cardiovascular Drugs Market by Top Key Players are Merck & Co., Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Bayer AG, Novartis AG, Gilead Sciences, Inc., AstraZeneca Forecast till 2026 For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/cardiovascular-therapeutics-market-100379
Singapore pharmaceutical market is anticipated to grow at a CAGR of 6.40% during the forecast period. Singapore medical device market is estimated to reach over USD 530 million by 2024.
Breast Cancer Therapeutics Market 2019 Industry Demand, Share, Global Trend, Industry News, Business Growth, Top Key Players Update, Business Statistics, and Research Methodology by Forecast to 2025
Rapid advancements in the technology involved in medical devices, coupled with introduction of innovative medical devices require specialized and smart packing solutions, which boosts the medical device packaging market growth.
The report on Cardiovascular Implants Market by drug class (disease modifying anti-rheumatic, nonsteroidal anti-inflammatory, corticosteroids, uric acid drugs), disease indication (rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, ankylosing spondylitis), distribution channel (hospital, retail, online pharmacy) trends analysis and forecasts up to 2023 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Cardiovascular Implants Market is projected to grow at a CAGR of 6.1% in terms of value over the period of 2017-2023. The growth in the world market is primarily driven by significant contribution by North America (Leading region) region to this market.
Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.
BMI 25 but 30 is overweight. BMI 30 is obese (BMI 40 ... Sleep apnoea. Jung R T. Obesity as a disease. Br Med Bull 1997;53:307-21. Why is it a problem? ...
The report "Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.
Proprietary Drug Discovery Technology. GPCRs Strategic drug development targets ... Commitment to discovery triad: Computational and medicinal chemistry ...
Future Market Insights (FMI) offers a 10-year forecast of the Europe viscosupplementation market between 2016 and 2026. In terms of value, the market is expected to register a CAGR of 5.1% over the forecast period. This study demonstrates market dynamics and trends that influence the current environment and future status of the viscosupplementation market in Europe over the forecast period. Report Description This Future Market Insights report examines the Europe viscosupplementation market for the period 2016–2026. The primary objective of the report is to offer insights on various viscosupplementation products such as single injection viscosupplementation, three injection viscosupplementation and five injection Viscosupplementation. The report also covers product pipeline analysis to understand market dynamics and patients preference for various product types.
Bharat Book presents the report on “Spinal Intervention: Markets for Surgical, Replacement and Neurostimulation Technologies” (https://www.bharatbook.com/healthcare-market-research-reports-622785/spinal-intervention-markets-surgical-replacement-neurostimulation.html). It provides readers with a broad understanding of the market for spinal interventional products, as well as the markets for adjacent but complementary products and technologies.
More than 840,000 new liver cancer cases were diagnosed around the world in 2018, according to the World Cancer Research Fund (WCRF). Similarly, other severe diseases, such as kidney cancer, aneurysms, and varicose veins, are also increasing in prevalence due to genetic predisposition, environmental factors, sedentary lifestyle, obesity, and alcohol abuse. The treatment or management of many such issues requires deliberately blocking the blood vessels to reduce the risk of bleeding or hemorrhage or to starve the tumor of blood, by inserting a balloon.